Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Continues Post-patent Prevacid Hit, Looks Externally For Innovation And Leadership

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda, like most Japanese pharma, is hoping to counter the ongoing trend of patent expirations and yen appreciation by looking outward. Pushing beyond their comfort zones of Japan and U.S. markets, Japan's top pharma are pushing to gain ground in Europe and Asia. Similarly, these companies are looking outside of their own staff for expertise in these new regions

You may also be interested in...



Takeda CEO Calls For A Paradigm Shift In Japanese R&D; BIO Japan Conference Takeaway Message, Head West...To China

Hasegawa encouraged Japanese companies to embrace a paradigm shift in their approach to R&D, which includes being open to reverse innovation and rethinking how global R&D can be localized

Takeda CEO Calls For A Paradigm Shift In Japanese R&D; BIO Japan Conference Takeaway Message, Head West...To China

Hasegawa encouraged Japanese companies to embrace a paradigm shift in their approach to R&D, which includes being open to reverse innovation and rethinking how global R&D can be localized

Takeda CEO Calls For A Paradigm Shift In Japanese R&D; BIO Japan Conference Takeaway Message, Head West...To China

YOKOHAMA, Japan - Takeda Pharmaceutical Co. CEO Yasuchika Hasegawa encouraged his fellow Japanese companies to embrace a paradigm shift in their approach to R&D, which includes being open to reverse innovation and rethinking how global R&D can be localized

Related Content

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel